20
Mar
2020
Biotech Can Help the Most Vulnerable. Here’s Are a Few Ways
Please subscribe and tell your friends why it’s worthwhile. Quality journalism costs money. When you subscribe to Timmerman Report at $169 per year, you reward quality independent biotech reporting, and encourage more. Subscribe Now Sign in to your account.
19
Mar
2020
COVID-19 Response – the Roadmap Not Followed
Please subscribe and tell your friends why it’s worthwhile. Quality journalism costs money. When you subscribe to Timmerman Report at $169 per year, you reward quality independent biotech reporting, and encourage more. Subscribe Now Sign in to your account.
19
Mar
2020
Singapore: What We Can Learn From a High-Risk Country’s Response to COVID19
I was born in Malaysia, but left my family for the promised land of Singapore at the age of 12 under a scholarship program known as the ASEAN program. I lived more than half my life in that country, and have long since become a Singaporean. I currently manage a major Singaporean life sciences VC fund from a San Francisco... Read More
19
Mar
2020
The Biopharmaceutical Counterattack
Please subscribe and tell your friends why it’s worthwhile. Quality journalism costs money. When you subscribe to Timmerman Report at $169 per year, you reward quality independent biotech reporting, and encourage more. Subscribe Now Sign in to your account.
18
Mar
2020
8 Days Later: Italy vs. US
The following is an update to my article on March 10, also published on Timmerman Report. The initial article is available (free to read here). Before I begin, I would like to sincerely thank everybody who has reached out with comments / feedback after my first article. Thank you also for the outpouring of well wishes for my family in... Read More
17
Mar
2020
Dangerous Shortages of Equipment: A Nurse’s View from the Front Lines of Pandemic
Please subscribe and tell your friends why it’s worthwhile. Quality journalism costs money. When you subscribe to Timmerman Report at $169 per year, you reward quality independent biotech reporting, and encourage more. Subscribe Now Sign in to your account.
17
Mar
2020
Solid Tumors Have Eluded CAR-T, But Novel Targets and Techniques Are At Hand
Please subscribe and tell your friends why it’s worthwhile. Quality journalism costs money. When you subscribe to Timmerman Report at $169 per year, you reward quality independent biotech reporting, and encourage more. Subscribe Now Sign in to your account.
16
Mar
2020
The Value And Necessity Of Tinkering
This week, I reviewed for the Wall Street Journal a pair of books about the increasing use of experimentation by businesses and other organizations: Experimentation Works, by Harvard Business School professor Stefan Thomke, and The Power of Experiments, by Michael Luca and Max Bazerman, also of Harvard Business School. These books in some ways represent the sequel to one of... Read More
14
Mar
2020
Life on the Front Lines of the COVID-19 Pandemic
The Massachusetts General Hospital COVID-19 Surge Clinic is a converted parking garage normally used as the ambulance bay for the Emergency Department. It is isolated from the rest of the ED by two sets of sliding glass doors and can only be accessed by badge. The garage has blue fluorescent lights and no windows, making it impossible to tell day... Read More
12
Mar
2020
COVID-19: Collective Problem-Solving Time
The alarm bells have been ringing for weeks. Stunningly, millions of people in the US weren’t listening, or didn’t want to listen. We have wasted precious time in defending ourselves against the coronavirus pandemic. The horrible news from Italy is slowly starting to sink in for us in the US, and other parts of the world. Sports cancellations, a prime-time... Read More
10
Mar
2020
Lessons from Italy: How the US Can Respond to the Urgent Coronavirus Threat
As background: I am Italian-born, and was raised in Italy. My entire family works and lives there, mostly in Milan or nearby areas. I have been communicating with family members about the noval coronavirus for the last month. I have a PhD in Molecular Biology from Geneva, Switzerland, and I have been in biotechnology venture capital since the early 2000s.... Read More
9
Mar
2020
Our Tightly Networked World: Blessing and Curse
Technology has been hailed for its ability to connect us; we’ve tended to view this is a positive development, but as rare, high-impact events like the coronavirus epidemic reminds us, a densely-networked world may also be more fragile. The mixed blessing of interconnectivity was acknowledged back in 2005 by New York Times columnist Thomas Friedman, who observed: “…we are now... Read More
9
Mar
2020
Living Life Fully with Stage 4 Lung Cancer: Isabella de le Houssaye on The Long Run
Today’s guest on The Long Run is Isabella de la Houssaye. Isabella is a former attorney on Wall Street, a mother of five kids, and a terrific endurance athlete. She’s run marathons around the country, ultramarathons, and even completed an Ironman triathlon. She’s also a Stage 4 lung cancer patient. She owes her life, and her vitality, to some extraordinary... Read More
5
Mar
2020
COVID-19 Spreads in Seattle, Gilead’s $4.9B Cancer Bet, & Thermo Grabs Qiagen
Everywhere I look — to the North, South, East and West of my home office in Seattle — there are confirmed cases of Covid-19. It’s one thing to read about a distant outbreak and intellectually understand the pandemic math, the morbidity and mortality rates, and responsible steps for containment and mitigation. It’s another thing to live in the middle of... Read More
3
Mar
2020
AGBT 2020 Recap: Partying Like It’s 1999
Please subscribe and tell your friends why it’s worthwhile. Quality journalism costs money. When you subscribe to Timmerman Report at $169 per year, you reward quality independent biotech reporting, and encourage more. Subscribe Now Sign in to your account.
2
Mar
2020
Reconceiving the Value of Curative Therapies
Please subscribe and tell your friends why it’s worthwhile. Quality journalism costs money. When you subscribe to Timmerman Report at $169 per year, you reward quality independent biotech reporting, and encourage more. Subscribe Now Sign in to your account.
27
Feb
2020
Gilead, Moderna Rise to the Occasion, Esperion Goes Back-to-Back, & Sangamo’s Big Neurology Deal
This week’s Frontpoints is a compilation of two weeks of deals, financings, and personnel moves. Coronavirus Thoughts If we learn one big lesson from this public health crisis, it should be that we need to continue to invest in our public agencies dedicated to science and public health – CDC, NIH and FDA, for starters. We also need to continue... Read More
24
Feb
2020
Facing Up to a Political Crisis: BIO Chairman Jeremy Levin on The Long Run
Please subscribe and tell your friends why it’s worthwhile. Quality journalism costs money. When you subscribe to Timmerman Report at $169 per year, you reward quality independent biotech reporting, and encourage more. Subscribe Now Sign in to your account.
24
Feb
2020
Dissecting Biotech’s Living and Walking Dead
Please subscribe and tell your friends why it’s worthwhile. Quality journalism costs money. When you subscribe to Timmerman Report at $169 per year, you reward quality independent biotech reporting, and encourage more. Subscribe Now Sign in to your account.
18
Feb
2020
Techlash Offers Health And Tech Opportunity To Reset Relationship, Rediscover Mutual Respect
Technology companies are experiencing a staggering reversal of reputational (though not financial) fortune; their stature seems reduced with each successive news cycle. Gone is the halo many tech companies once enjoyed. The implicit (and often explicit) assumption that tech innovation inevitably makes the world a better place has been replaced by real concerns that the picture may be far more... Read More